Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript. The company maintains a strong balance sheet with low gearing (0.16) and a positive net cash balance of Rs. 22 crores at standalone level. Plans to invest in CAPEX are funded through internal accruals and cash flow, with no stated intention to raise external funds. No specific comments on raising new debt or equity capital for expansion or other purposes during the earnings call. Management appears focused on operational growth, acquisitions (like Sanar Hospital), and franchise

Any current/future capex/capital investment/strategic investment?

FY '25 CAPEX for hospital business: ~Rs. 36 crores for existing units (new and replacement equipment). Additional Rs. 60-65 crores CAPEX planned for 3 new units/locations. Post Sanar Hospital acquisition (Rs. 206 crores), planned capacity expansion from 130 beds to 200 beds in coming years. Mumbai project: awaiting handover, expecting approvals soon; estimated 3 years for full facility after approvals. Nashik project: waiting for handover; currently no capital employed from Shalby. Implant business: significant investments in supply chain efficiencies and capacity expansions with cos

Future growth expectations in sales/revenue/volumes?

The implant business aims to grow from Rs. 100 crores to $100 million (~Rs. 850-900 crores) in about 5 years. Implant revenue target for FY '25 is $16 million, split equally between the U.S. and other international markets. Sales growth pillar focuses on increasing U.S. sales from $4.8 million currently to $8 million by onboarding distributors, expanding sales team, and marketing. Outside U.S., another $8 million is targeted through sales in Southeast Asia, Latin America, Russia, and other countries with better reimbursements. Franchise business plans to expand from current 5 operational franc

Future growth expectations in earnings/operating earnings/profits/EPS?

Implant business profitability is expected to improve to 9%-10% EBITDA margin by FY '26, and further to 18%-20% by FY '28-'29. Consolidated sales grew 15.2% in FY '24; EBITDA grew 22.8%, PBT 30%, and PAT 28.5% over FY '23, indicating strong earnings growth trajectory. Standalone hospital ROCE improved to 18% annualized in Q4 FY '24, with revenue growing at 25% CAGR since 2017 and EBITDA at 30% CAGR, signaling efficient profitable growth. Sanar business is reaching breakeven and expected to deliver positive EBITDA next quarter, contributing to consolidated profits. Marketing spend expec

ShalbyQ4 FY24Healthcare Services

Shalby Q4 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹128.95P/E: 35.4Market Cap: ₹1.4K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

The implant business aims to grow from Rs. 100 crores to $100 million (~Rs. 850-900 crores) in about 5 years.
Implant revenue target for FY '25 is $16 million, split equally between the U.S. and other international markets.
Sales growth pillar focuses on increasing U.S. sales from $4.8 million currently to $8 million by onboarding distributors, expanding sales team, and marketing.
Outside U.S., another $8 million is targeted through sales in Southeast Asia, Latin America, Russia, and other countries with better reimbursements.
Franchise business plans to expand from current 5 operational franchises to 30-50 franchisees across India over the next 3-5 years.
Home Care business is targeted to reach approximately 5% of hospital revenues; with Rs. 850 crores hospital revenue, Home Care can reach Rs. 40+ crores. It grew 50% last year.
Overall revenue grew 15%-20% in FY24 with continued focus on operational efficiencies and capacity expansion.

Margin guidance

Category 3

Implant business profitability is expected to improve to 9%-10% EBITDA margin by FY '26, and further to 18%-20% by FY '28-'29.
Consolidated sales grew 15.2% in FY '24; EBITDA grew 22.8%, PBT 30%, and PAT 28.5% over FY '23, indicating strong earnings growth trajectory.
Standalone hospital ROCE improved to 18% annualized in Q4 FY '24, with revenue growing at 25% CAGR since 2017 and EBITDA at 30% CAGR, signaling efficient profitable growth.
Sanar business is reaching breakeven and expected to deliver positive EBITDA next quarter, contributing to consolidated profits.
Marketing spend expected to remain stable at 1%-2% of revenue, controlling costs for margin sustainability.
Multi-vendor supply chain and new product launches planned to reduce implant COGS by 30% by year-end, supporting margin expansion.
Overall, the company targets high single-digit to double-digit profit growth in coming years with margin expansion from operational efficiency and scale.

See what Shalby management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
The company maintains a strong balance sheet with low gearing (0.16) and a positive net cash balance of Rs. 22 crores at standalone level.
Plans to invest in CAPEX are funded through internal accruals and cash flow, with no stated intention to raise external funds.
No specific comments on raising new debt or equity capital for expansion or other purposes during the earnings call.
Management appears focused on operational growth, acquisitions (like Sanar Hospital), and franchise expansion funded by existing resources.

Order book

The transcript does not provide specific details about current or expected order book or pending orders for Shalby Limited. The discussion primarily covers financial performance, business outlook, expansion plans such as franchise development, implant business growth, and operational metrics. No explicit mention or quantification of order book or pending orders is found in the provided pages of the transcript.

See what Shalby management said on order book — free account, 30 seconds.

Capex plans

Yes

FY '25 CAPEX for hospital business: ~Rs. 36 crores for existing units (new and replacement equipment).
Additional Rs. 60-65 crores CAPEX planned for 3 new units/locations.
Post Sanar Hospital acquisition (Rs. 206 crores), planned capacity expansion from 130 beds to 200 beds in coming years.
Mumbai project: awaiting handover, expecting approvals soon; estimated 3 years for full facility after approvals.
Nashik project: waiting for handover; currently no capital employed from Shalby.
Implant business: significant investments in supply chain efficiencies and capacity expansions with cost reductions targeted by end FY '25; ongoing investments to support $16 million implant revenue goal.
Franchise expansion: aiming for 30-50 franchises across India in next 3-5 years, with Rajkot franchise operational soon.

Track Shalby — get its next earnings analysis in your feed

How does Shalby rank vs peers in Healthcare Services?

Pro feature

ThisShalby

Rev 3Mar 3

See where Shalby sits in Healthcare ServicesSee which companies these are, and every other name in the sector.Open rankings

How does Shalby rank in Healthcare Services?

Compare Shalby against every Healthcare Services company (Q4 FY24) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

What Shalby's management said in earlier quarters

Others in Healthcare Services this season

Aatmaj Healthcare Ltd (Q1 FY27)
Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again
Maitreya Medica. (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medica.'s Q2 FY26 investor presentation — and how it ranks against sector peers.
Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
Suven Life Scie. (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su

Compare:vs Apollo Hospitals vs Manipal Health Enterprises Ltd vs Max Healthcare Institute Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Shalby Q4 FY24 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Shalby rank in Healthcare Services?

Continue your research

What Shalby's management said in earlier quarters

Others in Healthcare Services this season